Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer's disease
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved..
The high failure rate of clinical trials in Alzheimer's disease (AD) and AD-related dementia (ADRD) is due to a lack of understanding of the pathophysiology of disease, and this deficit may be addressed by applying artificial intelligence (AI) to "big data" to rapidly and effectively expand therapeutic development efforts. Recent accelerations in computing power and availability of big data, including electronic health records and multi-omics profiles, have converged to provide opportunities for scientific discovery and treatment development. Here, we review the potential utility of applying AI approaches to big data for discovery of disease-modifying medicines for AD/ADRD. We illustrate how AI tools can be applied to the AD/ADRD drug development pipeline through collaborative efforts among neurologists, gerontologists, geneticists, pharmacologists, medicinal chemists, and computational scientists. AI and open data science expedite drug discovery and development of disease-modifying therapeutics for AD/ADRD and other neurodegenerative diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Cell reports. Medicine - 5(2024), 2 vom: 20. Feb., Seite 101379 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheng, Feixiong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 25.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xcrm.2023.101379 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368724751 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368724751 | ||
| 003 | DE-627 | ||
| 005 | 20240425232935.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xcrm.2023.101379 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM368724751 | ||
| 035 | |a (NLM)38382465 | ||
| 035 | |a (PII)S2666-3791(23)00608-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheng, Feixiong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer's disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a The high failure rate of clinical trials in Alzheimer's disease (AD) and AD-related dementia (ADRD) is due to a lack of understanding of the pathophysiology of disease, and this deficit may be addressed by applying artificial intelligence (AI) to "big data" to rapidly and effectively expand therapeutic development efforts. Recent accelerations in computing power and availability of big data, including electronic health records and multi-omics profiles, have converged to provide opportunities for scientific discovery and treatment development. Here, we review the potential utility of applying AI approaches to big data for discovery of disease-modifying medicines for AD/ADRD. We illustrate how AI tools can be applied to the AD/ADRD drug development pipeline through collaborative efforts among neurologists, gerontologists, geneticists, pharmacologists, medicinal chemists, and computational scientists. AI and open data science expedite drug discovery and development of disease-modifying therapeutics for AD/ADRD and other neurodegenerative diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Wang, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yadi |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Zhimin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Pengyue |e verfasserin |4 aut | |
| 700 | 1 | |a Haines, Jonathan L |e verfasserin |4 aut | |
| 700 | 1 | |a Leverenz, James B |e verfasserin |4 aut | |
| 700 | 1 | |a Gan, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Jianying |e verfasserin |4 aut | |
| 700 | 1 | |a Rosen-Zvi, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Pieper, Andrew A |e verfasserin |4 aut | |
| 700 | 1 | |a Cummings, Jeffrey |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d 2020 |g 5(2024), 2 vom: 20. Feb., Seite 101379 |w (DE-627)NLM310587662 |x 2666-3791 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2024 |g number:2 |g day:20 |g month:02 |g pages:101379 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xcrm.2023.101379 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2024 |e 2 |b 20 |c 02 |h 101379 | ||